Research

Hormonal

Semaglutide (Ozempic/Wegovy) promotes significant weight loss (10-15% body weight) and improves glycemic control in adults with type 2 diabetes or obesity through GLP-1 receptor agonism, delayed gastric emptying, and appetite suppression.

Semaglutide is a once-weekly injection that mimics a gut hormone to slow digestion and reduce appetite. It is clinically proven to help people with obesity or type 2 diabetes lose 10-15% of their body weight when combined with diet and exercise. Side effects like nausea are common initially but often subside; starting with a low dose helps manage this. It is not a substitute for lifestyle changes but a tool to facilitate them.

GoodSupportsHIGH confidence
Ozempic effectively lowers blood glucose levels and supports weight loss in patients with type 2 diabetes and obesity... Clinical trials have demonstrated its superiority over other antidiabetic medications, with significant reductions in HbA1c and body weight.
Anna Maria Koman et al. · Quality in Sport · 2024

Why this rating

Based on a review of multiple Phase 3 trials (SUSTAIN, STEP) and regulatory approvals, though it is a review paper, not a primary trial.

Source

Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications

Anna Maria Koman et al. · Quality in Sport · 2024

DOI 10.12775/qs.2024.16.52659

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →